Teva appoints general manager in Germany
This article was originally published in Scrip
Teva Pharmaceutical Industries has made several appointments in Germany following its acquisition of Ratiopharm. It appointed Dr Sven Dethlefs, previously CEO of Teva Germany, as general manager of Ratiopharm. Oliver Windholz, Ratiopharm's former chairman, will oversee integration of Teva's European headquarters in Utrecht, the Netherlands, as chief operating officer until the end of this year, after which will leave the company. Dr Walter Buhl will continue as head of production in Germany, and Dr Gerald Huber will take over Teva's R&D operations in Europe. Dr Hermann Allgaier will head late-stage commercial production of Ratiopharm's biopharmaceutical and biogeneric products after its integration into Teva's business, and Dr Karl Heinz Emmert will be responsible for the development of biosimilars.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.